ADHD Medication Shortages Raise Concerns Among Young Patients and Their Families
According to the National Community Pharmacists Association, 97% of independent pharmacy owners reported shortages of Adderall in early 2023.
Over Half of At-Home Ketamine Users Misuse the Treatment
A new report recommended that ketamine therapy be used only in combination with psychotherapy under the supervision of a clinician.
First Treatment for Agitation Associated With Alzheimer Disease Dementia Approved by FDA
Data from two phase 3 studies showed that brexpiprazole 2 mg or 3 mg doses significantly improved symptoms of agitation in patients with AAD.
Balancing Risks and Rewards: Are Alzheimer Disease Treatments Worse Than the Illness?
How can current Alzheimer disease treatments be used to best treat patients living with the disease?
2a Trial of Psychedelic for Major Depressive Disorder Shows Positive Results
SPL026 with supportive therapy sees positive results in patients with major depressive disorder.
FDA Releases Notice on Safety and Effectiveness of Certain Nonprescription Naloxone Products
We may be one step closer to nonprescription naloxone.
Optimizing ADHD Treatment in Adults
ADHD is an all-day affair, and treating it in an adult population can be difficult.
Bone Density Negatively Impacted by ADHD Drugs
Recent research determined the psychostimulants modafinil, atomoxetine, and guanfacine negatively impact bones.
Advocating for Increased Access to Medication for Treating Opioid Use Disorder
The National Commission on Correctional Health Care and 166 other national organizations recently signed a letter to Senate leadership advocating for increased access to buprenorphine.
COVID-19: An Attack on the Brain
What are the long term psychiatric and neuropsychiatric complications of COVID-19?
FDA Asks for More Info on Expanded Use of Pimavanserin
Alzheimer disease psychosis treatment pimavanserin receives Complete Response Letter from the FDA.
Medication Treating Alcohol Use Disorder Shows Promise in Trial
Positive results from the phase 3 trial of AD04 show a 79% reduction in heavy drinking.
ASCEND Phase 2 Clinical Trial for Dextromethorphan-Bupropion Produces Positive Results
Axsome Therapeutics announced the robust antidepressant efficacy demonstrated in this latest study.
How Socioeconomic Factors Can Impact Depression Treatment
Home environments have a clear impact on depression treatment outcomes.
Relationship Between Unhealthy Eating, ADHD in Children Examined
A recent study found a negative association between children with ADHD and health eating patterns.
FDA Approves Dexmedetomidine Sublingual Film for Acute Agitation
The new drug treats acute agitation associated with schizophrenia, bipolar I, or bipolar II in adults.
Depression a Consequence of Health Disparities Among Sexual Minorities
According to research examining sexual minority patients, depression can be a consequence of health and behavioral disparities.
Spotlight: Issues in ADHD
Catch up on all the latest in ADHD from the virtual APSARD 2022 Annual Meeting.
Zuranolone Study Meets Endpoints for Major Depression Disorder Treatment
Zuranolone treatment in patients with major depressive disorder demonstrates a rapid and statistically significant reduction in depressive symptoms.
Evidence-Based Solutions for Stopping the Opioid Crisis
A coalition of 240 organizations came together to urge Congress to pass legislation to fight the opioid crisis.
Unique Pharmacokinetic Profile, Range of Dosing Options WIth New FDA Approved ADHD Treatment
The FDA has approved Dyanavel XR, extended release once-daily tablets for the treatment of attention-deficit/hyperactivity disorder.
First Participant Enrolled in Trial for Vaccine to Treat Opioid Disorders
A vaccine that prevents oxycodone from entering the brain? This might be the safe, long-lasting, cost-effective solution for opioid use disorders.
7 Recommendations from the AMA to Reduce the Opioid Crisis
The American Medical Association is urging policymakers to act now to prevent further opioid overdose deaths.
2 Clarke Drive Cranbury, NJ 08512